Evidence map›Paper›PMID 33390858›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology

Neoadjuvant chemotherapy with or without oxaliplatin after short-course radiotherapy in high-risk rectal cancer: A subgroup analysis from a prospective study.

Ewa Kosakowska, Lucyna Pietrzak, Wojciech Michalski, Lucyna Kepka, Wojciech Polkowski, Malgorzata Jankiewicz, Bogumila Cisel, Jacek Krynski, Jacek Zwolinski, Lucjan Wyrwicz and 8 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Ewa KosakowskaDepartment of Gastroenterological Oncology, Maria Sklodowska-Curie National, Research Institute of Oncology, Warsaw, Poland.
Lucyna PietrzakI Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Wojciech MichalskiDepartment of Computational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Lucyna KepkaDepartment of Radiotherapy, Military Institute of Medicine, Warsaw, Poland.
Wojciech PolkowskiDepartment of Surgical Oncology, Medical University of Lublin, Poland.
Malgorzata JankiewiczDepartment of Radiotherapy, St. John's Cancer Center, Lublin, Poland.
Bogumila CiselDepartment of Surgical Oncology, Medical University of Lublin, Poland.
Jacek KrynskiDepartment of Gastroenterological Oncology, Maria Sklodowska-Curie National, Research Institute of Oncology, Warsaw, Poland.
Jacek ZwolinskiDepartment of Gastroenterological Oncology, Maria Sklodowska-Curie National, Research Institute of Oncology, Warsaw, Poland.
Lucjan WyrwiczDepartment of Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Andrzej RutkowskiDepartment of Gastroenterological Oncology, Maria Sklodowska-Curie National, Research Institute of Oncology, Warsaw, Poland.
Roman Stylinski1st Department of General Surgery, Transplantology and Nutritional Therapy, Medical University of Lublin, Poland.
Grzegorz NawrockiDepartment of Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Rafal SopyloDepartment of Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Marek SzczepkowskiClinical Department of Colorectal, General and Oncological Surgery, Centre of Postgraduate Medical Education, Bielanski Hospital, Warsaw, Poland.
Wieslaw TarnowskiDepartment of General, Oncologic and Digestive Tract Surgery, Medical Centre of Postgraduate Education, Orlowski Hospital, Warsaw, Poland.
Krzysztof BujkoI Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Polish Colorectal Study Group
The Maria Sklodowska-Curie National Research Institute of Oncology · PLMedical University of Lublin · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the role of oxaliplatin in neoadjuvant chemotherapy delivered after short-course irradiation.

backgroundUsing oxaliplatin in the above setting is uncertain. PATIENTS AND

methodsA subgroup of 136 patients managed by short-course radiotherapy and 3 cycles of consolidation chemotherapy within the framework of a randomised study was included in this post-hoc analysis. Sixty-seven patients received FOLFOX4 (oxaliplatin group) while oxaliplatin was omitted in the second period of accrual in 69 patients because of protocol amendment (fluorouracil-only group).

resultsGrade 3+ acute toxicity from neoadjuvant treatment was observed in 30% of patients in the oxaliplatin group vs. 16% in the fluorouracil-only group (

conclusionOur findings do not support adding oxaliplatin to three cycles of chemotherapy delivered after short-course irradiation.

Indexed as

Neoadjuvant chemotherapyOxaliplatinRectal cancer

Identifiers

PMID33390858
PMCPMC7772602
OpenAlexW3049589680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.